HNRNPA2B1 and lymphoma: The IHC results showed that HNRNPA2B1 was highly expressed in breast cancer, cervical cancer, colorectal cancer, endometrial cancer, GBM, head and neck cancer, liver cancer, lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, testis cancer, urothelial cancer, KIRC, etc. (Figures 2(a), 2(b), 2(c), 2(d), 2(e), 2(f), 2(g), 2(h), 2(i), 2(j), 2(k), 2(l), 2(m), 2(n), 2(o), 2(p), 2(q), and 2(r)).